Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer.

MLA

Musolino, A., et al. “Immunoglobulin G Fragment C Receptor Polymorphisms and Efficacy of Preoperative Chemotherapy plus Trastuzumab and Lapatinib in HER2-Positive Breast Cancer.” The Pharmacogenomics Journal, vol. 16, no. 5, Oct. 2016, pp. 472–77. EBSCOhost, https://doi.org/10.1038/tpj.2016.51.

APA

Musolino, A., Naldi, N., Dieci, M. V., Zanoni, D., Rimanti, A., Boggiani, D., Sgargi, P., Generali, D. G., Piacentini, F., Ambroggi, M., Cagossi, K., Gianni, L., Sarti, S., Bisagni, G., Ardizzoni, A., Conte, P. F., & Guarneri, V. (2016). Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. The Pharmacogenomics Journal, 16(5), 472–477. https://doi.org/10.1038/tpj.2016.51

Chicago

Musolino, A, N Naldi, M V Dieci, D Zanoni, A Rimanti, D Boggiani, P Sgargi, et al. 2016. “Immunoglobulin G Fragment C Receptor Polymorphisms and Efficacy of Preoperative Chemotherapy plus Trastuzumab and Lapatinib in HER2-Positive Breast Cancer.” The Pharmacogenomics Journal 16 (5): 472–77. doi:10.1038/tpj.2016.51.